EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation

Haroon Afzal, Asad Murtaza, Li-Ting Cheng

Molecular Biology Reports · 2025-12 · 52 (1)

DOI: 10.1007/s11033-024-10146-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, online erschienen am 07.01.2025. Verfasst von Haroon Afzal und 2 weiteren Autor:innen. Beteiligte Einrichtung: International Degree Program of Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, 1, Shuefu R…. Hauptthemen laut MEDLINE: Adjuvants, Vaccine, Flagellin, Toll-Like Receptor 5. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UiT The Arctic University of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flagellin stimulates Toll-like receptor 5 (TLR5), triggering both innate and adaptive immune responses, making it a potential vaccine adjuvant. On mucosal surfaces, flagellin induces a strong release of cytokines, chemokines, and immunoglobulins. When used in its free monomeric form, flagellin has been shown to enhance immune responses when combined with vaccine antigens. Further research demonstrated that genetically linking flagellin to the antigen provides a more consistent immune boost. However, the bulky structure of flagellin presents challenges in designing the antigen-adjuvant construct, leading to ongoing research to determine the minimal flagellin domain necessary for its adjuvant effect. Early findings suggest that only the D0 and D1 domains are required for immune enhancement. Functional analysis revealed that the TLR5-binding region is located in the D1 domain, while TLR5 dimerization and signaling require the presence of D0. Further reductions in the size of the D0 and D1 domains may be possible as deeper studies aim to identify the key residues responsible for TLR5 activation and immune enhancement. Additionally, flagellin is being tested as a hapten carrier alongside its established adjuvant role. Recently, significant advancements in flagellin application have been observed as it progresses through clinical studies as an adjuvant, anti-radiation, and anti-cancer agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, VaccineFlagellinToll-Like Receptor 5AnimalsHumansProtein DomainsSignal Transduction

Stichwörter der Autor:innen

AdjuvantDimerizationFlagellinHaptenTLR5

Substanzen

Adjuvants, VaccineFlagellinTLR5 protein, humanToll-Like Receptor 5

Autor:innen und Institutionen

  • International Degree Program of Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, 1, Shuefu Road, Neipu, Pingtung, 91201, Taiwan.
  • International Degree Program of Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, 1, Shuefu Road, Neipu, Pingtung, 91201, Taiwan. Asad.murtaza@uit.no.
  • Norwegian College of Fishery Science, Faculty of Biosciences, Fisheries and Economics, UiT - The Arctic University of Norway, Tromsø, Norway. Asad.murtaza@uit.no.
  • International Degree Program of Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, 1, Shuefu Road, Neipu, Pingtung, 91201, Taiwan. chenglt@mail.npust.edu.tw.
  • Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, 1, Shuefu Road, Neipu, Pingtung, 91201, Taiwan. chenglt@mail.npust.edu.tw.

Förderung

  • UiT The Arctic University of Norway

Zitieren

APA

Afzal, H., Murtaza, A., & Cheng, L. T. (2025). Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation. Molecular Biology Reports, 52(1). https://doi.org/10.1007/s11033-024-10146-y

Vancouver

Afzal H, Murtaza A, Cheng LT. Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation. Molecular Biology Reports. 2025;52(1). doi:10.1007/s11033-024-10146-y

BibTeX
@article{Afzal2025,
  author = {Afzal, Haroon and Murtaza, Asad and Cheng, Li-Ting},
  title = {Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation},
  journal = {Molecular Biology Reports},
  year = {2025},
  volume = {52},
  number = {1},
  doi = {10.1007/s11033-024-10146-y}
}
Kostenlos starten →